Physician profile

Robyn Strum

Family · Tinley Park, IL

NPI 1275905283

$1,081.82

in general payments reported to CMS, 2019-2025

9 companies · $7.92 in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$543.89
Education$60.99

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Abbvie INC. $581.00 2021-2024
Conmed Corporation $134.46 2024 Conmed Hemostasis, Conmed Generators
Gilead Sciences, INC. $124.97 2024 Epclusa
Allergan, INC. $88.09 2021
Janssen Biotech, INC. $86.19 2023-2024 Stelara
Takeda Pharmaceuticals U.S.A., INC. $31.38 2022
Merck Sharp & Dohme LLC $14.55 2023 Dificid
Nestle Healthcare Nutrition INC. $13.26 2021
Phathom Pharmaceuticals, INC. $7.92 2025 Voquezna

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Robyn Strum

$1,081.82

in general payments reported 2019-2025

Years
2021-2025
Top company
Abbvie INC.

https://glasscript.com/doctor/10574209/robyn-strum

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.